Page Title
Drug Development Pipeline
Back to the Drug Development Pipeline
Docosahexaenoic Acid (DHA)
Status
DiscontinuedTherapeutic Approach
Anti-Inflammatory
Docosahexaenoic acid (DHA) is an omega-3 fatty acid with anti-inflammatory properties.
Status
No further clinical development in CF is planned at this time.
Sponsor
The program was fully funded through the Cystic Fibrosis Foundation.
Recent Changes
10/1/2012

CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More